HK1117424A1 - Use of low dose local immune suppression to enhance oncolytic viral therapy - Google Patents

Use of low dose local immune suppression to enhance oncolytic viral therapy

Info

Publication number
HK1117424A1
HK1117424A1 HK08112289.7A HK08112289A HK1117424A1 HK 1117424 A1 HK1117424 A1 HK 1117424A1 HK 08112289 A HK08112289 A HK 08112289A HK 1117424 A1 HK1117424 A1 HK 1117424A1
Authority
HK
Hong Kong
Prior art keywords
low dose
immune suppression
viral therapy
local immune
oncolytic viral
Prior art date
Application number
HK08112289.7A
Other languages
English (en)
Chinese (zh)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of HK1117424A1 publication Critical patent/HK1117424A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK08112289.7A 2006-02-13 2008-11-07 Use of low dose local immune suppression to enhance oncolytic viral therapy HK1117424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77306806P 2006-02-13 2006-02-13
US78889806P 2006-04-03 2006-04-03
PCT/CA2007/000187 WO2007093036A1 (fr) 2006-02-13 2007-02-09 Utilisation d'immunosuppression locale pour améliorer une thérapie virale oncolytique

Publications (1)

Publication Number Publication Date
HK1117424A1 true HK1117424A1 (en) 2009-01-16

Family

ID=38371138

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112289.7A HK1117424A1 (en) 2006-02-13 2008-11-07 Use of low dose local immune suppression to enhance oncolytic viral therapy

Country Status (13)

Country Link
US (1) US20070190032A1 (fr)
EP (1) EP1984007B1 (fr)
JP (1) JP2009525989A (fr)
AR (1) AR059482A1 (fr)
AU (1) AU2007215328A1 (fr)
BR (1) BRPI0707654A2 (fr)
CA (1) CA2640286C (fr)
DK (1) DK1984007T3 (fr)
ES (1) ES2551306T3 (fr)
HK (1) HK1117424A1 (fr)
IL (1) IL192211A0 (fr)
TW (1) TW200744618A (fr)
WO (1) WO2007093036A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003556A (es) * 2007-10-22 2010-04-21 Oncolytics Biotech Inc Regimen de tratamiento para trastornos proliferantes.
WO2009135614A2 (fr) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Utilisation d’un régime viral dans le traitement de maladies
CN102695520A (zh) * 2008-05-27 2012-09-26 昂科利蒂克斯生物科技公司 调节间隙压力与溶瘤病毒的递送和分布
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2010020056A1 (fr) * 2008-08-21 2010-02-25 Ottawa Hospital Research Institute Symbiose virale oncolytique synergique obtenue par génie génétique
FI20100329A0 (fi) * 2010-09-24 2010-09-24 Antti Alitalo Immunomodulatorinen adjuvanttihoito
CA2834532A1 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Nanovecteurs synthetiques tolerogenes destines a reduire des reponses impliquant des lymphocytes t cytotoxiques
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
CA2909432A1 (fr) 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Therapie cellulaire adoptive amelioree
US10357482B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
KR20240123409A (ko) 2014-09-07 2024-08-13 셀렉타 바이오사이언시즈, 인크. 유전자 편집 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
WO2016201450A2 (fr) * 2015-06-11 2016-12-15 University Of Miami Traitement et diagnostic du cancer
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3931221A1 (fr) 2019-03-01 2022-01-05 Rampart Health, L.L.C. Composition pharmaceutique associant un procédé immunologique et chimiothérapeutique pour le traitement du cancer
CA3208059A1 (fr) 2021-02-12 2022-08-18 David Granger BOSTWICK Composition therapeutique et procede combinant une immunotherapie multiplex avec un vaccin contre le cancer pour le traitement du cancer
WO2023078574A1 (fr) * 2021-11-08 2023-05-11 Sveuciliste U Zagrebu Kit pharmaceutique pour virothérapie oncolytique du cancer du sein, sa préparation et son utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5614403A (en) * 1994-06-01 1997-03-25 Baylor College Of Medicine In vitro replication system capable of rescuing cloned and manipulated rotavirus genes
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
ES2273408T3 (es) * 1997-04-03 2007-05-01 Electrofect As. Metodo para introducir medicamentos y acidos nucleicos en el musculo esqueletico.
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
WO2000029033A2 (fr) * 1998-11-17 2000-05-25 The General Hospital Corporation Technique d'apport de vecteurs genetiques
US20020187465A1 (en) * 1999-11-12 2002-12-12 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
EP1227828A1 (fr) * 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Virus pour le traitement des troubles de la proliferation cellulaire
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
WO2002012285A2 (fr) * 2000-08-10 2002-02-14 Board Of Regents, The University Of Texas System Suppresseur de tumeur car-1
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
CA2428206C (fr) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Procedes de traitement de troubles de la proliferation cellulaire
US7198783B2 (en) * 2002-05-10 2007-04-03 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with reovirus
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
US20070017123A1 (en) * 2005-07-25 2007-01-25 Rogue Outdoor Brands, Llc Insert for footwear midsole

Also Published As

Publication number Publication date
BRPI0707654A2 (pt) 2011-05-10
EP1984007B1 (fr) 2015-08-19
AR059482A1 (es) 2008-04-09
TW200744618A (en) 2007-12-16
WO2007093036A1 (fr) 2007-08-23
CA2640286C (fr) 2018-01-02
CA2640286A1 (fr) 2007-08-23
DK1984007T3 (en) 2015-12-07
AU2007215328A1 (en) 2007-08-23
EP1984007A1 (fr) 2008-10-29
US20070190032A1 (en) 2007-08-16
AU2007215328A2 (en) 2008-07-31
ES2551306T3 (es) 2015-11-17
EP1984007A4 (fr) 2012-03-07
JP2009525989A (ja) 2009-07-16
IL192211A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
HK1117424A1 (en) Use of low dose local immune suppression to enhance oncolytic viral therapy
HRP20182194T1 (hr) Onkolitički herpes simpleks virus i njegova terapeutska uporaba
EP2491033A4 (fr) Azaindazoles pour traiter une infection par le virus flaviviridae
PT3042910T (pt) 2'-espiro-nucleósidos para utilização na terapia da hepatite c
ZA201304114B (en) Human antibodies to human tnf-like ligang 1a (tl1a)
PL2627334T3 (pl) Kompozycje do stosowania w leczeniu zakażeń wirusowych
EP2552203A4 (fr) Composés et compositions pharmaceutiques pour le traitement d'infections virales
HK1246149A1 (zh) 溶瘤牛痘病毒組合癌症療法
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
EP2633865A4 (fr) Utilisation d'interleukine 22 dans le traitement d'une hépatite virale
EP2326327A4 (fr) Analogues d'indole-3-carbinol et leur utilisation comme agents contre une infection
EP2094293A4 (fr) Activation antigénique de la réponse immunitaire ciblée sur des tissus pour traiter des cancers
EP2370068A4 (fr) Procédés et compositions pour la délivrance de médicaments aux poumons
IL213593A0 (en) Hepatitis c virus combination therapy
EP2121764A4 (fr) Complexes de polyédres viraux et procédés d'utilisation
EP2249826A4 (fr) Compositions et procédés d utilisation de composés pour augmenter le temps de survie de patients atteints du cancer
ZA200806750B (en) Use of local immune suppression to enhance oncolytic viral therapy
EP2298344A4 (fr) Utilisation d une particule du virus inactivé de l encéphalite japonaise comme adjuvant
EP2618825A4 (fr) Utilisation de la nigéricine pour traiter et prévenir des infections par le virus de la vaccine
ZA201205056B (en) Therapeutic use of protein-polymer conjugates
GB0821361D0 (en) Use of silane-treated particles in laminates to improve clarity
EP2504347A4 (fr) Amplification de l'effet thérapeutique de l'acupuncture par l'adénosine
GB201014736D0 (en) Treatment of hepatitis C
IL207197A0 (en) Targeting of innate immune response to tumor site
GB201012168D0 (en) Treatment of viral infections